➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Harvard Business School
Johnson and Johnson
Express Scripts
Dow

Last Updated: October 18, 2021

DrugPatentWatch Database Preview

Pfizer Company Profile


Email this page to a colleague

« Back to Dashboard

Summary for Pfizer

Drugs and US Patents for Pfizer

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer CAVERJECT alprostadil INJECTABLE;INJECTION 020755-001 Oct 31, 1997 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial
Pfizer DOXORUBICIN HYDROCHLORIDE doxorubicin hydrochloride INJECTABLE;INJECTION 050467-003 May 20, 1985 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial
Pfizer FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-004 Jan 30, 1998 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial
Pfizer MEDROL methylprednisolone TABLET;ORAL 011153-002 Approved Prior to Jan 1, 1982 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial
Pfizer SINEQUAN doxepin hydrochloride CAPSULE;ORAL 016798-003 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Pfizer

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer MICRONASE glyburide TABLET;ORAL 017498-001 May 1, 1984 3,426,067 ⤷  Free Forever Trial
Pfizer MINIPRESS XL prazosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 019775-001 Jan 29, 1992 4,092,315 ⤷  Free Forever Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-001 Jan 29, 1997 5,457,109 ⤷  Free Forever Trial
Pfizer COVERA-HS verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020552-001 Feb 26, 1996 4,612,008 ⤷  Free Forever Trial
Pfizer Inc CAMPTOSAR irinotecan hydrochloride INJECTABLE;INJECTION 020571-001 Jun 14, 1996 6,403,569*PED ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for PFIZER drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 75 mg/0.2 mg ➤ Subscribe 2008-11-28
➤ Subscribe Extended-release Tablets 4 mg and 8 mg ➤ Subscribe 2012-10-31
➤ Subscribe Injection 20 mg/mL, 2 mL and 5 mL vials ➤ Subscribe 2004-07-26
➤ Subscribe Capsules 5 mg and 10 mg ➤ Subscribe 2005-06-21
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe 2011-06-17
➤ Subscribe Oral Suspension 100 mg/5 mL ➤ Subscribe 2009-08-03
➤ Subscribe Injection 2 mg/mL, 100 mL bag ➤ Subscribe 2009-12-29
➤ Subscribe Tablets 5 mg ➤ Subscribe 2016-11-07
➤ Subscribe Delayed-release Tablets 50 mg/0.2 mg ➤ Subscribe 2009-06-29
➤ Subscribe Extended-release Tablets 11 mg ➤ Subscribe 2016-11-07
➤ Subscribe Capsules 20 mg, 40 mg, 60 mg and 80 mg ➤ Subscribe 2005-02-07
➤ Subscribe Capsules 75 mg, 100 mg and 125 mg ➤ Subscribe 2019-02-04
➤ Subscribe Capsules 0.125 mg, 0.25 mg, and 0.5 mg ➤ Subscribe 2014-05-01
➤ Subscribe Tablets 600 mg ➤ Subscribe 2005-12-21
➤ Subscribe Injection 2 mg/mL, 300 mL bag ➤ Subscribe 2009-09-01
➤ Subscribe Tablets 1 g ➤ Subscribe 2005-08-23

Supplementary Protection Certificates for Pfizer Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1470124 C01470124/01 Switzerland ⤷  Free Forever Trial PRODUCT NAME: PALBOCICLIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66138 31.01.2017
2822953 C201930063 Spain ⤷  Free Forever Trial PRODUCT NAME: LORLATINIB O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO.; NATIONAL AUTHORISATION NUMBER: EU/1/19/1355; DATE OF AUTHORISATION: 20190506; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1355; DATE OF FIRST AUTHORISATION IN EEA: 20190506
0126587 96C0023 Belgium ⤷  Free Forever Trial PRODUCT NAME: MEROPENEM TRIHYDR; NAT. REGISTRATION NO/DATE: 624 IS 88 F 12 19960205; FIRST REGISTRATION: IT 028949028 19940817
2170860 36/2020 Austria ⤷  Free Forever Trial PRODUCT NAME: GLASDEGIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, EINSCHLIESSLICH DES MALEATSALZES; REGISTRATION NO/DATE: EU/1/20/1451/001 (MITTEILUNG) 20200629
2767537 122019000108 Germany ⤷  Free Forever Trial PRODUCT NAME: TALAZOPARIB ODER PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1377 20190620
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Harvard Business School
Moodys
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.